CO5011054A1 - Compuestos triciclicos sustituidos - Google Patents
Compuestos triciclicos sustituidosInfo
- Publication number
- CO5011054A1 CO5011054A1 CO99022897A CO99022897A CO5011054A1 CO 5011054 A1 CO5011054 A1 CO 5011054A1 CO 99022897 A CO99022897 A CO 99022897A CO 99022897 A CO99022897 A CO 99022897A CO 5011054 A1 CO5011054 A1 CO 5011054A1
- Authority
- CO
- Colombia
- Prior art keywords
- group
- substituted
- hydrogen
- carbon
- sulfur
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 5
- 239000001257 hydrogen Substances 0.000 abstract 5
- 230000002452 interceptive effect Effects 0.000 abstract 5
- 125000001424 substituent group Chemical group 0.000 abstract 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 4
- 229910052799 carbon Inorganic materials 0.000 abstract 4
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 3
- 239000002253 acid Substances 0.000 abstract 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 3
- 229910052760 oxygen Inorganic materials 0.000 abstract 3
- 239000001301 oxygen Substances 0.000 abstract 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 3
- 229910052717 sulfur Inorganic materials 0.000 abstract 3
- 239000011593 sulfur Substances 0.000 abstract 3
- 125000004429 atom Chemical group 0.000 abstract 2
- 229910052757 nitrogen Inorganic materials 0.000 abstract 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 abstract 1
- 150000002431 hydrogen Chemical class 0.000 abstract 1
- 125000005647 linker group Chemical group 0.000 abstract 1
- 230000003287 optical effect Effects 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/80—[b, c]- or [b, d]-condensed
- C07D209/82—Carbazoles; Hydrogenated carbazoles
- C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/58—[b]- or [c]-condensed
- C07D209/70—[b]- or [c]-condensed containing carbocyclic rings other than six-membered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Communicable Diseases (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US6232898A | 1998-04-17 | 1998-04-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO5011054A1 true CO5011054A1 (es) | 2001-02-28 |
Family
ID=22041763
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO99022897A CO5011054A1 (es) | 1998-04-17 | 1999-04-16 | Compuestos triciclicos sustituidos |
| CO99022884A CO5031247A1 (es) | 1998-04-17 | 1999-04-16 | Compuestos triciclicos sustituidos |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO99022884A CO5031247A1 (es) | 1998-04-17 | 1999-04-16 | Compuestos triciclicos sustituidos |
Country Status (30)
| Country | Link |
|---|---|
| EP (2) | EP0952149B1 (enExample) |
| JP (2) | JPH11322713A (enExample) |
| KR (2) | KR100586761B1 (enExample) |
| CN (1) | CN1149193C (enExample) |
| AR (2) | AR018186A1 (enExample) |
| AT (2) | ATE268756T1 (enExample) |
| AU (2) | AU753547B2 (enExample) |
| BR (2) | BR9902365A (enExample) |
| CA (2) | CA2269262A1 (enExample) |
| CO (2) | CO5011054A1 (enExample) |
| CZ (2) | CZ137099A3 (enExample) |
| DE (2) | DE69917833T2 (enExample) |
| DK (1) | DK0950657T3 (enExample) |
| DZ (1) | DZ2769A1 (enExample) |
| EA (2) | EA002347B1 (enExample) |
| ES (2) | ES2222663T3 (enExample) |
| HU (2) | HUP9901221A3 (enExample) |
| ID (2) | ID23761A (enExample) |
| IL (2) | IL129485A0 (enExample) |
| NO (2) | NO312240B1 (enExample) |
| NZ (3) | NZ507564A (enExample) |
| PE (2) | PE20000432A1 (enExample) |
| PL (2) | PL332565A1 (enExample) |
| PT (1) | PT950657E (enExample) |
| SG (2) | SG81977A1 (enExample) |
| SI (1) | SI0950657T1 (enExample) |
| TR (2) | TR199900843A2 (enExample) |
| TW (1) | TWI238160B (enExample) |
| YU (2) | YU18999A (enExample) |
| ZA (2) | ZA992772B (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6610728B2 (en) * | 1997-08-28 | 2003-08-26 | Eli Lilly And Company | Method for treatment of non-rheumatoid arthritis |
| DZ2769A1 (fr) * | 1998-04-17 | 2003-12-01 | Lilly Co Eli | Composés tricycliques substitués. |
| CA2358492A1 (en) * | 1998-12-21 | 2000-06-29 | Eli Lilly And Company | Combination therapy for the treatment of sepsis |
| DE60032774D1 (de) * | 1999-07-19 | 2007-02-15 | Lilly Co Eli | Spla2 inhibitoren |
| US6706752B1 (en) | 1999-07-19 | 2004-03-16 | Eli Lilly And Company | sPLA2 inhibitors |
| DE60130891T2 (de) * | 2000-06-29 | 2008-07-17 | Anthera Pharmaceuticals Inc., San Mateo | Heilmittel für krebs |
| WO2002000256A1 (fr) * | 2000-06-29 | 2002-01-03 | Shionogi & Co., Ltd. | Remedes contre la cirrhose |
| WO2002000257A1 (en) * | 2000-06-29 | 2002-01-03 | Shionogi & Co., Ltd. | Remedies for alzheimer's disease |
| CN1450893A (zh) * | 2000-07-14 | 2003-10-22 | 伊莱利利公司 | 治疗脓毒症的方法 |
| AU2002239263A1 (en) | 2000-12-18 | 2002-07-01 | Eli Lilly And Company | Tetracyclic carbazole derivates and their use as spla2 inhibitors |
| DE60218155D1 (de) | 2001-03-28 | 2007-03-29 | Lilly Co Eli | Substituierte carbazole als inhibitoren von spla2 |
| AUPS282602A0 (en) | 2002-06-07 | 2002-06-27 | Garvan Institute Of Medical Research | Method of inhibiting cell proliferation |
| DE10249055A1 (de) | 2002-10-22 | 2004-05-06 | Bayer Cropscience Ag | 2-Phenyl-2-substituierte-1,3-diketone |
| JO3598B1 (ar) | 2006-10-10 | 2020-07-05 | Infinity Discovery Inc | الاحماض والاسترات البورونية كمثبطات اميد هيدروليز الحامض الدهني |
| EP1988098A1 (en) * | 2007-04-27 | 2008-11-05 | AEterna Zentaris GmbH | Novel Tetrahydrocarbazole Derivatives as Ligands of G-protein Coupled Receptors |
| WO2009119534A1 (ja) | 2008-03-26 | 2009-10-01 | 第一三共株式会社 | 新規テトラヒドロイソキノリン誘導体 |
| AU2009233711B2 (en) | 2008-04-09 | 2015-02-12 | Infinity Pharmaceuticals, Inc | Inhibitors of fatty acid amide hydrolase |
| US8580795B2 (en) | 2009-01-22 | 2013-11-12 | Orchid Chemicals & Pharmaceuticals Limited | Heterocyclic compounds as phosphodiesterase inhibitors |
| WO2010118155A1 (en) | 2009-04-07 | 2010-10-14 | Infinity Pharmaceuticals, Inc. | Inhibitors of fatty acid amide hydrolase |
| WO2010118159A1 (en) | 2009-04-07 | 2010-10-14 | Infinity Pharmaceuticals, Inc. | Inhibitors of fatty acid amide hydrolase |
| BR112012019120A2 (pt) | 2010-02-03 | 2016-06-28 | Infinity Pharmaceuticais Inc | forma sólida, composição farmacêutica, método de preparação do composto 1, método de tratamento de uma condição mediada por faah |
| AR088377A1 (es) | 2011-10-20 | 2014-05-28 | Siena Biotech Spa | Proceso para la preparacion de 6-cloro-2,3,4,9-tetrahidro-1h-carbazol-1-carboxamida y compuestos intermedios de esta |
| CN102816107B (zh) * | 2012-08-20 | 2015-06-03 | 东南大学 | 咔唑衍生物及其制备方法与用途 |
| WO2014083163A1 (en) | 2012-11-30 | 2014-06-05 | Ge Healthcare Limited | Zinc halide mediated cyclization process leading to tricyclic indoles |
| RU2015118217A (ru) | 2012-11-30 | 2017-01-11 | ДжиИ ХЕЛТКЕР ЛИМИТЕД | Способ кристаллизации трициклических индольных производных |
| WO2016116527A1 (de) * | 2015-01-20 | 2016-07-28 | Cynora Gmbh | Organische moleküle, insbesondere zur verwendung in optoelektronischen bauelementen |
| CN108707104A (zh) * | 2018-08-07 | 2018-10-26 | 北京恒信卓元科技有限公司 | 2-氯-1h-咔唑-1,4(9h)-二酮的合成方法 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3579534A (en) * | 1969-05-09 | 1971-05-18 | American Cyanamid Co | Tetrahydrocarbazolecarboxylates |
| US3979391A (en) * | 1972-11-22 | 1976-09-07 | Sterling Drug Inc. | 1,2,3,4-Tetrahydrocarbazoles |
| US3939177A (en) * | 1972-11-22 | 1976-02-17 | Sterling Drug Inc. | 4-Aminomethyl-9-benzyl-1,2,3,4-tetrahydrocarbazoles |
| PT95692A (pt) * | 1989-10-27 | 1991-09-13 | American Home Prod | Processo para a preparacao de derivados de acidos indole-,indeno-,piranoindole- e tetra-hidrocarbazole-alcanoicos, ou quais sao uteis como inibidores de pla2 e da lipoxigenase |
| US5420289A (en) * | 1989-10-27 | 1995-05-30 | American Home Products Corporation | Substituted indole-, indene-, pyranoindole- and tetrahydrocarbazole-alkanoic acid derivatives as inhibitors of PLA2 and lipoxygenase |
| JPH06509087A (ja) * | 1991-07-05 | 1994-10-13 | メルク シヤープ エンド ドーム リミテツド | 芳香族化合物、それらを含む医薬組成物、及び治療におけるそれらの使用 |
| MY110227A (en) * | 1991-08-12 | 1998-03-31 | Ciba Geigy Ag | 1-acylpiperindine compounds. |
| IL109309A (en) * | 1993-04-16 | 2000-06-29 | Lilly Co Eli | 1-H-indole-3-acetic acid hydrazide SPLA2 inhibitors and pharmaceutical compositions containing them |
| IL109311A0 (en) * | 1993-04-16 | 1994-07-31 | Lilly Co Eli | 1H-indole-3-acetamide sPla2 inhibitors |
| EP0749962B1 (en) * | 1995-06-23 | 2000-11-02 | Eli Lilly And Company | 6-substituted-1,2,3,4-tetrahydro-9H-carbazoles and 7-substituted-10H-cyclohepta(7,6-B)indoles |
| DE69614232T2 (de) * | 1995-12-13 | 2002-01-10 | Eli Lilly And Co., Indianapolis | Naphthyl-Acetamide als sPLA2-Inhibitoren |
| KR20000049210A (ko) * | 1996-10-30 | 2000-07-25 | 피터 지. 스트링거 | 치환된 트리시클릭류 |
| AU9664198A (en) * | 1997-09-26 | 1999-04-23 | Eli Lilly And Company | Method for the treatment of cystic fibrosis |
| JP2001522884A (ja) * | 1997-11-14 | 2001-11-20 | イーライ・リリー・アンド・カンパニー | アルツハイマー病の処置方法 |
| DZ2769A1 (fr) * | 1998-04-17 | 2003-12-01 | Lilly Co Eli | Composés tricycliques substitués. |
-
1999
- 1999-04-14 DZ DZ990069A patent/DZ2769A1/xx active
- 1999-04-15 IL IL12948599A patent/IL129485A0/xx unknown
- 1999-04-15 ID IDP990341D patent/ID23761A/id unknown
- 1999-04-15 IL IL12948399A patent/IL129483A0/xx unknown
- 1999-04-15 ID IDP990340D patent/ID23287A/id unknown
- 1999-04-16 ZA ZA9902772A patent/ZA992772B/xx unknown
- 1999-04-16 PL PL99332565A patent/PL332565A1/xx not_active Application Discontinuation
- 1999-04-16 AR ARP990101770A patent/AR018186A1/es not_active Application Discontinuation
- 1999-04-16 BR BR9902365-2A patent/BR9902365A/pt not_active IP Right Cessation
- 1999-04-16 JP JP11109629A patent/JPH11322713A/ja not_active Withdrawn
- 1999-04-16 AR ARP990101771A patent/AR018593A1/es active IP Right Grant
- 1999-04-16 SG SG9901869A patent/SG81977A1/en unknown
- 1999-04-16 EP EP99302941A patent/EP0952149B1/en not_active Expired - Lifetime
- 1999-04-16 HU HU9901221A patent/HUP9901221A3/hu unknown
- 1999-04-16 PL PL99332566A patent/PL332566A1/xx not_active Application Discontinuation
- 1999-04-16 CZ CZ991370A patent/CZ137099A3/cs unknown
- 1999-04-16 DE DE69917833T patent/DE69917833T2/de not_active Expired - Lifetime
- 1999-04-16 NZ NZ507564A patent/NZ507564A/xx unknown
- 1999-04-16 SI SI9930650T patent/SI0950657T1/xx unknown
- 1999-04-16 NZ NZ335251A patent/NZ335251A/xx unknown
- 1999-04-16 CN CNB991079574A patent/CN1149193C/zh not_active Expired - Fee Related
- 1999-04-16 YU YU18999A patent/YU18999A/sh unknown
- 1999-04-16 NO NO19991822A patent/NO312240B1/no not_active IP Right Cessation
- 1999-04-16 DE DE69918590T patent/DE69918590T2/de not_active Expired - Lifetime
- 1999-04-16 TR TR1999/00843A patent/TR199900843A2/xx unknown
- 1999-04-16 AT AT99302941T patent/ATE268756T1/de not_active IP Right Cessation
- 1999-04-16 DK DK99302967T patent/DK0950657T3/da active
- 1999-04-16 YU YU19199A patent/YU19199A/sh unknown
- 1999-04-16 EA EA199900301A patent/EA002347B1/ru not_active IP Right Cessation
- 1999-04-16 ES ES99302941T patent/ES2222663T3/es not_active Expired - Lifetime
- 1999-04-16 ES ES99302967T patent/ES2226286T3/es not_active Expired - Lifetime
- 1999-04-16 PT PT99302967T patent/PT950657E/pt unknown
- 1999-04-16 PE PE1999000314A patent/PE20000432A1/es not_active Application Discontinuation
- 1999-04-16 SG SG9901681A patent/SG81976A1/en unknown
- 1999-04-16 KR KR1019990013438A patent/KR100586761B1/ko not_active Expired - Fee Related
- 1999-04-16 PE PE1999000320A patent/PE20000476A1/es not_active Application Discontinuation
- 1999-04-16 BR BR9901279-0A patent/BR9901279A/pt not_active IP Right Cessation
- 1999-04-16 CO CO99022897A patent/CO5011054A1/es unknown
- 1999-04-16 EP EP99302967A patent/EP0950657B1/en not_active Expired - Lifetime
- 1999-04-16 NO NO19991821A patent/NO314400B1/no not_active IP Right Cessation
- 1999-04-16 AU AU23819/99A patent/AU753547B2/en not_active Ceased
- 1999-04-16 CZ CZ991369A patent/CZ136999A3/cs unknown
- 1999-04-16 JP JP15240099A patent/JP4435330B2/ja not_active Expired - Fee Related
- 1999-04-16 HU HU9901220A patent/HUP9901220A3/hu unknown
- 1999-04-16 KR KR1019990013436A patent/KR19990083232A/ko not_active Withdrawn
- 1999-04-16 ZA ZA9902771A patent/ZA992771B/xx unknown
- 1999-04-16 CA CA002269262A patent/CA2269262A1/en not_active Abandoned
- 1999-04-16 CO CO99022884A patent/CO5031247A1/es unknown
- 1999-04-16 EA EA199900303A patent/EA002816B1/ru not_active IP Right Cessation
- 1999-04-16 CA CA002269246A patent/CA2269246C/en not_active Expired - Fee Related
- 1999-04-16 TW TW088106130A patent/TWI238160B/zh not_active IP Right Cessation
- 1999-04-16 NZ NZ335253A patent/NZ335253A/xx unknown
- 1999-04-16 AT AT99302967T patent/ATE271037T1/de active
- 1999-04-16 AU AU23817/99A patent/AU753436B2/en not_active Ceased
- 1999-04-16 TR TR1999/00853A patent/TR199900853A2/xx unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO4920250A1 (es) | Compuestos heterociclicos utiles en la inhibicion de la spla2 | |
| AU584428B2 (en) | (Meth) -Acrylic acid esters and the use thereof | |
| AR018593A1 (es) | COMPUESTOS TRICICLICOS SUSTITUIDOS, FORMULACIoN FARMACÉUTICA QUE LO COMPRENDE, USO DE DICHO COMPUESTO PARA FABRICAR UN MEDICAMENTO uTIL PARA INHIBIR SELECTIVAMENTE SPLA2 Y ALIVIAR EFECTOS PATOLoGICOS DE ENFERMEDADES RELACIONADAS | |
| CO5080728A1 (es) | Compuestos triciclicos sustituidos | |
| DE3781716D1 (de) | Mittel zur ortsspezifischen alkylierung. | |
| NO20013379L (no) | 4-okso-1,4-dihydro-3-kinolinkarboksamider som antivirusmidler | |
| AR009212A1 (es) | Un derivado de 3-piperidil-4-oxoquinazolina; una composicion farmaceutica, un inhibidor de la proteina de transferencia de los trigliceridos microsomal(mtp) y un agente terapeutico o preventivo para la hiperlipemia o la arteriosclerosis que lo contienen | |
| EA200100428A1 (ru) | Производные тетрагидробензазепина, полезные в качестве модуляторов допаминовых d3 рецепторов (антипсихотические агенты) | |
| ID21568A (id) | Penggunaan baru untuk turunan 1,3-propanadiol | |
| EA200100310A1 (ru) | Кислородсодержащие гетероциклические соединения | |
| ES8302783A1 (es) | "un procedimiento para preparar un compuesto de inclusion de ciclodextrina". | |
| YU12992A (sh) | 2-amino-1,2,3,4,-tetrahidronaftaleni supstituisani u prstenu | |
| ES2121183T3 (es) | Ligandos selectivos de los receptores 5ht1d-5ht1b derivados de indol-piperacina utiles como medicamentos. | |
| DK0471266T3 (da) | Anvendelse af cooligomerer af (meth)acrylsyreestere og alfa-olefiner som synteseolier inden for smøring | |
| DE69326302D1 (de) | Pleuromutilin-derivate | |
| FI885036A0 (fi) | Hiilivetykoostumus, kuten polttoaineöljy, ja sen lisäaineet | |
| NO942757D0 (no) | 4-aryl-3-(heteroarylureido)-1,2-dihydro-2-okso-kinolin-derivater | |
| FI890520A0 (fi) | Foerfarande foer framstaellning av terapeutiskt anvaendbara 2- (piperidin-4-ylmetyl) -1,2,3,4 -tetrahydroisokinolinderivat. | |
| ES2190222T3 (es) | Derivados de 3-(2-oxo-(1,3')bipirrolindinil-3-iliden-metil)-cefem. | |
| NO900732D0 (no) | Arylalkylaminforbindelser. | |
| DK0524512T3 (da) | Antihypertensiv kombination | |
| FI853685A0 (fi) | Nya n-alk(en)yl-n-(o,o-disubstituerade -tiofosforyl)-n'n'-disubstituerade glycinamider, foerfarande foer framstaellning av dessa samt kvalstergifter, insektgifter och svampgifter vilka innehaoller dessa som aktiv bestaondsdel. | |
| ECSP941143A (es) | Indoles | |
| DK82583A (da) | Furyloxazolyleddikesyrederivater og fremgangsmaader til fremstilling deraf | |
| FI933468A0 (fi) | Tetrahydronaftalenderivat, framstaellning av dessa och terapeutisk anvaendning av dessa |